New name reflects company’s growth and vision to help bring certainty and transparency to global clinical trials

SINGAPORE, April 7, 2025 /PRNewswire/ — George Clinical, a leading clinical research organization (CRO) operating worldwide, is pleased to announce it has rebranded to become Emerald Clinical Trials. This strategic name change underscores the company’s well-established position as a dedicated, reliable, consistent, and flexible CRO, while mitigating global clinical development risks through deep therapeutic and local expertise cultivated over 20 years.

Emerald Clinical Trials continues to focus on end-to-end services across all therapeutic areas designed to change lives⁠ while ⁠advancing innovations that help evolve global clinical research practices. With its strong track record in Oncology and Cardio-Renal-Metabolic (CRM) therapeutic areas, trusted expertise in Asia Pacific, and global scientific leadership, Emerald Clinical Trials is a highly differentiated clinical CRO on the world stage. The company’s extensive reach – operating directly in 42 countries and in 70 countries through partnerships – ensures seamless execution of clinical trials worldwide.

The new brand amplifies the exceptional work of Emerald Clinical Trials and highlights the breadth and depth of its experience to an even broader audience. It emphasizes a strong commitment to patients, customers, and partners.

The company’s deep commitment to customer-centricity fosters long-term relationships built on trust, reliability, and measurable success. Emerald’s ability to deliver predictability in clinical trials is underscored by a track record of repeat business, industry excellence awards, and consistent performance in bringing therapies to market.

“For the past two decades, Emerald Clinical Trials has been focused on delivering high quality trials that combine a global reach with a high-touch approach. We offer the footprint and expertise of a large CRO with the personalized attention and flexibility of a smaller partner, ensuring that every client, from emerging biotech to top-tier pharma, receives the focused, hands-on support they need to de-risk their clinical programs,” said Mary Gunn, CEO, Emerald Clinical Trials. “This exciting transformation strengthens our position as a trusted partner in clinical trials, while reaffirming our commitment to our clients and core values.”

“We decided early on that we wanted to work with a CRO that has a flexible approach, and solutions tailored to the specific needs of each trial, whether accelerating timelines, adapting to evolving study requirements, or scaling resources efficiently,” said Dr. Daniel Tillett, CEO, Race Oncology, an Emerald client. “Agility is critical for biopharma companies that require a partner who can pivot alongside them, rather than slow them down with bureaucratic inefficiencies, and that is truly a strength of Emerald Clinical Trials.”

About Emerald Clinical Trials
Emerald Clinical Trials is a leading clinical research organization operating worldwide that serves over 100 biotechs, and 6 of the top 10 pharmaceutical companies. Headquartered in Singapore and driven by operational expertise and scientific excellence, the company provides comprehensive clinical trial services to clients globally, offering solutions across all trial phases. For more information, visit www.emeraldclinical.com.

Media Contact: Shannon Severino, shannon@severinocommunications.com, T +1 412 608 2393

Logo – https://mma.prnewswire.com/media/2657673/George_Clinical__Emerald_Clinical_Trials__logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/george-clinical-rebrands-as-emerald-clinical-trials-302420315.html

Court Bans NUC Juicer Sales in Europe, Orders Compensation, Recall, and Destruction of Infringing Products

SEOUL, South Korea, April 7, 2025 /PRNewswire/ — Hurom, the global pioneer in slow juicing and the inventor of the world’s first vertical juicer, has secured a major legal victory against NUC, maker of the Kuvings juicer line, in the Unified Patent Court (UPC) of Europe.

On March 11, the UPC’s regional division in Mannheim, Germany ruled that NUC—including its Korean headquarters, European subsidiary, and distributor Warmcook—had infringed Hurom’s European patent (EP2028981).

As a result, NUC is now banned from selling its juicers in Europe, with any violations subject to a fine of €2,000 per infringing unit sold.

The court also ordered NUC to compensate Hurom for damages and cover all litigation costs, as well as recall and destroy all infringing products already distributed in the market. One of the key products found to be in violation is the Kuvings AUTO10 juicer.

This ruling follows Hurom’s previous legal wins in South Korea and the United States, further reinforcing its position as the original innovator behind vertical juicing technology.

In December 2024, the Korea Trade Commission determined that NUC had infringed Hurom’s patents and engaged in unfair trade practices, issuing a corrective order and imposing a fine. Similarly, in July 2024, Amazon’s Amazon Patent Evaluation Express (APEX) process (APEX ID: 15060613361) confirmed NUC’s patent infringement, resulting in the suspension of several key Kuvings juicer models in the U.S. market.  

Hurom CEO Jaewon Kim commented, “This ruling is a strong affirmation of Hurom’s technological leadership on the global stage,” and added, “We will continue to take firm action against reckless patent infringement and low-cost knockoffs that compromise our mission of promoting health through fruit and vegetable consumption.”

*Unified Patent Court (Germany) Case Numbers: PR_ACT_17336/2024, PR_ACT_17365/2024

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/hurom-wins-patent-infringement-case-against-nuc-kuvings-in-european-unified-patent-court-302418281.html

SOURCE HUROM

SINGAPORE, April 6, 2025 /PRNewswire/ — Pertamina International Marketing & Distribution Pte. Ltd. (PIMD) has selected ADP Clear to drive its digital bunkering transformation, reinforcing its commitment to efficiency, compliance, and transparency. With over 8,000 bunker deliveries processed on its platform, ADP is the industry’s leading digital bunkering solution.

Part of Indonesia’s Pertamina group, PIMD aims to actively contribute to Singapore’s marine and bunker industry advancements, promoting technological innovations and sustainable practices to enhance the overall competitiveness and environmental responsibility of the sector.

As a company committed to operational excellence and digital transformation, PIMD recognises the critical role that data plays in ensuring accountability and efficiency. Under this partnership, PIMD will implement ADP Clear as its electronic Bunker Delivery Note (eBDN) solution, ensuring full compliance with Singapore MPA’s digital bunkering standards while optimising workflows across its fleet.

ADP will provide PIMD with real-time visibility and enhanced transparency, allowing the organisation to optimise its delivery processes and uphold the highest industry standards. This strategic approach accelerates PIMD’s growth trajectory to 200,000 tonnes of bunker deliveries per month across 5 barges, and paves the way for additional expansion and increased market share.

“By adopting ADP, we can enhance operational control, streamline our bunkering process, and reinforce trust within the maritime ecosystem. Moreover, with ADP’s dedicated global support team available around the clock, we have the confidence that expert assistance is always within reach. We look forward to our continued collaboration with ADP in shaping the future of digitalised bunkering,” said Justin Tan, Trading Manager of PIMD.

“ADP Clear is proud to collaborate with PIMD in its digital transformation, enhancing efficiency and transparency in bunkering operations. By leveraging ADP’s technology, PIMD is streamlining its supply chain, seamlessly managing over 50 deliveries per month, while driving operational excellence at scale. Together, we are setting new benchmarks for digital innovation in the industry,” said Eunice Low, Business Development Manager at ADP Clear.

Why ADP Clear? Advanced Delivery Platform is a multi-party workflow platform that streamlines the entire bunker requisition process. It enables real-time data transfer between all stakeholders, reducing manual work and errors. This results in:

Paperless Operations – eliminates manual documentation, saving time and resources.Real-Time Data & Accuracy – reduces human error, ensuring seamless data transfer.Unmatched Security – blockchain-powered protection that exceeds MPA regulations.Full Transparency – clear documentation of fuel quality, quantity, and delivery process. Barge certification documents are available in the platform.Operational Efficiency – instant data access enables smarter scheduling and decision-making.

About PIMD

PIMD is part of Pertamina Group, Indonesia’s state-owned energy giant. It operates as the international marketing and distribution arm in oil, gas, renewables, and petrochemicals. It is a key player in marine fuel trading in Singapore, committed to innovation and sustainability.

About ADP Clear

ADP Clear offers comprehensive digital bunkering solutions across 15 ports globally, processing more than 6 million metric tons of marine fuel on platform since 2021.

View original content to download multimedia:https://www.prnewswire.com/news-releases/adp-clear-partners-with-pimd-to-drive-digital-bunkering-transformation-in-singapore-302420967.html

SOURCE ADP Clear